CoChat

Germline TP53 Variants and Susceptibility to Osteosarcoma

Open access
Mirabello, Lisa, Yeager, Meredith, Mai, Phuong L., Gastier-Foster, Julie M., Gorlick, Richard, Khanna, Chand, Patiño-Garcia, Ana, Sierrasesúmaga, Luis, Lecanda, Fernando, Andrulis, Irene L., Wunder, Jay S., Gokgoz, Nalan, Barkauskas, Donald A., Zhang, Xijun, Vogt, Aurelie, Jones, Kristine, Boland, Joseph F., Chanock, Stephen J., Savage, Sharon A. · 2015 · JNCI Journal of the National Cancer Institute

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

The etiologic contribution of germline genetic variation to sporadic osteosarcoma is not well understood. Osteosarcoma is a sentinel cancer of Li-Fraumeni syndrome (LFS), in which approximately 70% of families meeting the classic criteria have germline TP53 mutations. We sequenced TP53 exons in 765 osteosarcoma cases. Data were analyzed with χ(2) tests, logistic regression, and Cox proportional hazards regression models. We observed a high frequency of young osteosarcoma cases (age <30 years) carrying a known LFS- or likely LFS-associated mutation (3.8%) or rare exonic variant (5.7%) with an overall frequency of 9.5%, compared with none in case patients age 30 years and older (P < .001). This high TP53 mutation prevalence in young osteosarcoma cases is statistically significantly greater than the previously reported prevalence of 3% (P = .0024). We identified a novel association between a TP53 rare variant and metastasis at diagnosis of osteosarcoma (rs1800372, odds ratio = 4.27, 95% confidence interval = 1.2 to 15.5, P = .026). Genetic susceptibility to young onset osteosarcoma is distinct from older adult onset osteosarcoma, with a high frequency of LFS-associated and rare exonic TP53 variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djv101

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 ger- mline mutation carriers. Cancer. 2012;118(5):1387-1396. · DOI · Paper page

Cited by

See all 170

Metadata

Authors
Mirabello, L., Yeager, M., Mai, P. L., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Patiño-Garcia, A., Sierrasesúmaga, L., Lecanda, F., Andrulis, I. L., Wunder, J. S., Gokgoz, N., Barkauskas, D. A., Zhang, X., Vogt, A., Jones, K., Boland, J. F., Chanock, S. J., & Savage, S. A.
Affiliations
University of Southern California (US)
Venue
JNCI Journal of the National Cancer Institute
Published
2015-04-20
Volume
107
Issue
7
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2056679196
Cited by
155
References
38
Citations by year
2026: 12 · 2025: 17 · 2024: 12 · 2023: 14 · 2022: 11 · 2021: 13 · 2020: 20 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 13 · 2015: 4
FWCI
10.81
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • Children’s Oncology Group (U10 CA180886)
  • National Institutes of Health (CA180886)
  • Canadian Institutes of Health Research
  • National Cancer Institute (CA114766, CA 180886, U24CA114766, U10CA180886)
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
osteosarcoma, TP53, germline mutations, Li-Fraumeni syndrome, genetic susceptibility, metastasis at diagnosis
MeSH terms
Adult, Bone Neoplasms, Female, Humans, Male, Osteosarcoma, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Age of Onset, Germ-Line Mutation, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.